Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is a aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal estrogen receptor‑positive breast cancer, helping to reduce estrogen‑driven tumor growth.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Accord is an aromatase inhibitor used in the management of hormone‑sensitive breast cancer. - Postmenopausal estrogen receptor‑positive breast cancer: reduces risk of disease recurrence. - Adjuvant therapy for hormone‑responsive breast cancer: improves disease‑free survival after surgery. - Metastatic estrogen receptor‑positive breast cancer: slows tumor progression and prolongs survival.

Adverse reactions may occur with Letrozol Accord and should be monitored.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in joints and muscles. - Nausea: mild stomach upset. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Severe liver injury: jaundice or markedly elevated liver enzymes. - Blood clots: deep‑vein thrombosis or pulmonary embolism. - Allergic reaction: rash, swelling, or difficulty breathing.

Before initiating therapy with Letrozol Accord, several safety considerations are recommended. - Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Assess liver function: perform baseline and periodic liver enzyme tests. - Evaluate cardiovascular risk: watch for signs of thrombosis or hypertension. - Avoid use in pregnancy: letrozole is contraindicated in pregnant women (Category X). - Use with caution in elderly patients: adjust monitoring for frailty and comorbidities. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Letrozol Accord can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: antagonizes letrozole’s effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower plasma concentrations. - Tamoxifen: opposing mechanisms may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect, monitor INR. - SSRIs (e.g., fluoxetine): may affect metabolism, observe for side‑effect changes. - Statins: possible increased risk of muscle toxicity, assess patient tolerance.